{"id":45749,"date":"2024-02-16T10:36:06","date_gmt":"2024-02-16T09:36:06","guid":{"rendered":"https:\/\/www.bricbordeaux.com\/2024\/02\/france-2030-funding-rhu-sprint-trio2-team\/"},"modified":"2024-04-04T12:10:56","modified_gmt":"2024-04-04T10:10:56","slug":"france-2030-funding-rhu-sprint-trio2-team","status":"publish","type":"post","link":"https:\/\/www.bricbordeaux.com\/en\/2024\/02\/france-2030-funding-rhu-sprint-trio2-team\/","title":{"rendered":"France 2030 funding: RHU SPRINT &#8211; TRIO2 team"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.bricbordeaux.com\/bric-team\/recherche-translationnelle-en-cancerologie-cutanee-et-maladies-cutanees-rares\/\" target=\"_blank\" rel=\"noreferrer noopener\">Team 5 of our TRIO2 unit (Translational Research on Oncodermatology and Rare skin diseases)<\/a> is heavily involved in the new <strong>RHU SPRINT<\/strong> project (Synergie Pour Acc\u00e9l\u00e9rer l&#8217;Innovation Th\u00e9rapeutique dans les lymphomes T cutan\u00e9s), coordinated by <strong>Pr Ad\u00e8le de Masson<\/strong> of the <a href=\"https:\/\/u-paris.fr\" target=\"_blank\" rel=\"noreferrer noopener\">Universit\u00e9 Paris Cit\u00e9<\/a>. RHU projects are funded by France 2030, coordinated by the ANR &#8211; Agence Nationale de la Recherche.<\/p>\n\n<p class=\"wp-block-paragraph\"><strong><a href=\"https:\/\/www.bricbordeaux.com\/people\/anne-pham-ledard\/\" target=\"_blank\" rel=\"noreferrer noopener\">Pr Anne Pham Ledard<\/a><\/strong> is the scientific manager in charge of the project for our team. The budget allocated to the team is : 775,008 euros out of a total RHU budget of over 9 million euros. It involves <strong><a href=\"https:\/\/www.bricbordeaux.com\/people\/sandrine-poglio\/\" target=\"_blank\" rel=\"noreferrer noopener\">Dr Sandrine Poglio<\/a><\/strong> and <strong><a href=\"https:\/\/www.bricbordeaux.com\/people\/jean-philippe-merlio\/\">Pr Jean-Philippe Merlio<\/a><\/strong><\/p>\n\n<p class=\"wp-block-paragraph\">Research on our TRIO2 team:<br\/>&#8211; Participation in the preclinical development of two innovative drugs for the treatment of cutaneous T lymphomas, using biological models of cell lines developed from patient cells.<br\/>&#8211; Understanding the biological mechanisms involved in response to treatment, through analysis of the tumor immune microenvironment using multiplexing techniques on skin biopsies from patients taking part in the Phase 1 clinical trial.<br\/><\/p>\n\n<p class=\"wp-block-paragraph\">The RHU SPRINT project also involves <a href=\"https:\/\/www.chu-bordeaux.fr\/Les-unit%C3%A9s-m%C3%A9dicales\/Dermatologie-canc%C3%A9rologique\/\" target=\"_blank\" rel=\"noreferrer noopener\">the oncology dermatology unit of the Dermatology Department of Bordeaux University Hospital<\/a>, whose members are <strong><a href=\"https:\/\/www.bricbordeaux.com\/people\/marie-beylot-barry\/\" target=\"_blank\" rel=\"noreferrer noopener\">Pr. Marie Beylot-Barry<\/a><\/strong> (co-leader of our TRIO2 team) is in charge. Other TRIO2 team members are also involved in the project at CHU level : <strong><a href=\"https:\/\/www.bricbordeaux.com\/people\/fanny-beltzung\/\" target=\"_blank\" rel=\"noreferrer noopener\">Dr Fanny Beltzung<\/a><\/strong> and <strong><a href=\"https:\/\/www.bricbordeaux.com\/people\/beatrice-vergier\/\" target=\"_blank\" rel=\"noreferrer noopener\">Pr B\u00e9atrice Vergier<\/a><\/strong>.<\/p>\n\n<p class=\"wp-block-paragraph\">Projects developed by the CHU part (Budget allocated to Bordeaux CHU: \u20ac279,730):<\/p>\n\n<p class=\"wp-block-paragraph\">&#8211; Creation of a database specific to the SPRINT project (WP1): clinical data, biological samples, histopathological and immunohistochemical images, treatments, results.<br\/>&#8211; The development of AI software for modeling the progression of cutaneous T lymphomas.<br\/>&#8211; Development of a drug for relapsed or refractory cutaneous T lymphomas (Co-leader for WP6 and investigating center for the Phase 1 trial, sponsor = APHP).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Team 5 of our TRIO2 unit (Translational Research on Oncodermatology and Rare skin diseases) is heavily involved in the new RHU SPRINT project (Synergie Pour Acc\u00e9l\u00e9rer l&#8217;Innovation Th\u00e9rapeutique dans les lymphomes T cutan\u00e9s), coordinated by Pr Ad\u00e8le de Masson of the Universit\u00e9 Paris Cit\u00e9. RHU&#8230;<\/p>\n","protected":false},"author":3,"featured_media":45743,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[111],"tags":[155,156],"class_list":["post-45749","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-rhu-en","tag-sprint-en"],"_links":{"self":[{"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/posts\/45749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/comments?post=45749"}],"version-history":[{"count":1,"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/posts\/45749\/revisions"}],"predecessor-version":[{"id":45750,"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/posts\/45749\/revisions\/45750"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/media\/45743"}],"wp:attachment":[{"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/media?parent=45749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/categories?post=45749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/tags?post=45749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}